Media Contact:
Brenda Patterson
SRPR
440.623.9581
brenda@shevrushpr.com

LEO Pharma Inc. Expands US Presence, Adds Jobs

Parsippany, NJ – December 22, 2011 – LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, makers of the Taclonex® brand of products, announced today a continuation of its U.S. expansion, which has included the addition of 201 employees across the country in the past 24 months.

LEO Pharma Inc. opened its headquarters in Parsippany, New Jersey in December 2009 with five employees. Since then, the company has added an additional 50 employees at its corporate headquarters and 151 employees to its nationwide sales force, including regional directors, district managers, and sales representatives.

LEO Pharma A/S is wholly owned by the LEO Foundation and headquartered in Ballerup, Denmark. The company has more than 100 years of history as an independent, research-based specialty pharmaceutical company committed to the discovery and development of novel drugs for patients within the areas of dermatology and critical care medicine.

"The values of LEO Pharma, which include integrity, innovation, and customer-focus, provide a solid platform for continued growth and differentiation here in the U.S.," said John Koconis, president and chief executive officer at LEO Pharma, Inc. "By building corporate capabilities in areas such as patient education, as well as expanding our representative base, LEO is further demonstrating our commitment to those dealing with plaque psoriasis."

LEO Pharma Inc. will continue to add in-house positions in marketing and sales training, as well as field-based positions including medical science liaisons and corporate account managers in 2011.

For more information, visit www.leo-pharma.us.

About LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more than 100 years of history as an independent, research-based specialty pharmaceutical company.

LEO Pharma A/S, makers of the Taclonex® brand of products, is wholly owned by the LEO Foundation. The company is developing a number of new products, including treatments for the skin disorders actinic keratosis and eczema.

To learn more about LEO Pharma Inc., visit www.leo-pharma.us.

About Taclonex® Ointment and Taclonex Scalp® Topical Suspension

Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment is approved for use on the skin to treat psoriasis vulgaris (plaque psoriasis) in adults 18 years of age and older and should be

applied to affected areas once daily for up to 4 weeks. Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension is approved to treat moderate to severe psoriasis vulgaris of the scalp in adults 18 years and older and should be applied to affected areas on the scalp once a day for 2 weeks or until cleared. If the affected area is not cleared, Taclonex Scalp® Topical Suspension may be continued for up to 8 weeks. Do not exceed the recommended weekly dose of 100 grams. Neither product is recommended for use on children.

IMPORTANT SAFETY INFORMATION ABOUT TACLONEX® OINTMENT AND TACLONEX SCALP® TOPICAL SUSPENSION

FOR TOPICAL USE ONLY. Do not use Taclonex® Ointment or Taclonex Scalp® Topical Suspension on your face, under your arms, or on your groin. Do not get either product in your eyes, mouth, or vaginal area. **Do not swallow Taclonex® Ointment or Taclonex Scalp® Topical Suspension**.

You should not use Taclonex® Ointment or Taclonex Scalp® Topical Suspension if you are allergic to any of their ingredients, have thin skin (atrophy) at the treatment site, have known or suspected calcium metabolism disorders (too much or too little calcium in your blood or urine), have erythrodermic, exfoliative, or pustular psoriasis, or have severe kidney or severe liver disease. Avoid excessive exposure to either natural or artificial sunlight if you apply Taclonex® Ointment to exposed portions of your body or use Taclonex Scalp® Topical Suspension. Tell your doctor if you have a skin infection, are getting phototherapy treatments for your psoriasis, are pregnant, or planning to become pregnant, or are breastfeeding. Also tell your doctor about other medicines you are taking, especially other corticosteroids, products containing calcipotriene, or medicines for your psoriasis.

Taclonex® Ointment and Taclonex Scalp® Topical Suspension each may cause serious side effects if you use too much, use them for too long, or use them with other medicines that contain corticosteroids or calcipotriene. Taclonex® Ointment and Taclonex Scalp® Topical Suspension contain the same medicine to treat psoriasis vulgaris. If you use both medicines to treat your psoriasis vulgaris, be sure to follow your doctor's directions carefully so that you do not use too much of one or both of these medicines. Taclonex® Ointment and Taclonex Scalp® Topical Suspension can pass through your skin. **Serious side effects may include too much calcium in your blood or urine or adrenal gland problems**. Your doctor may do special blood and urine tests to check your calcium levels and adrenal gland function while you are using Taclonex® Ointment or Taclonex Scalp® Topical Suspension.

The most common side effects of Taclonex® Ointment are itching and rash. Other less common side effects include redness of the skin, inflamed hair pores (folliculitis), skin irritation, skin burning, change of skin color (at the site of application), rash with pus-filled papules, thinning of the skin, and swollen fine blood vessels (this makes your skin appear red at the site of application).

The most common side effects of Taclonex Scalp® Topical Suspension are inflamed hair pores (folliculitis) and burning sensation of the skin. Other side effects include itching, worsening of psoriasis, redness of the skin, and skin pain or irritation.

Please see the full Prescribing Information at www.taclonex.com.